

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
06/28/2001	Tongtong Wang	210121.455C16	1354
7590 10/24/2003		EXAM	INER
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC		CHEN, SHIN LIN	
VE			
SUITE 6300		ART UNIT	PAPER NUMBER
SEATTLE, WA 98104-7092		1632	
	06/28/2001 7590 10/24/2003 LLECTUAL PROPER VE	06/28/2001 Tongtong Wang 7590 10/24/2003 LLECTUAL PROPERTY LAW GROUP PLLC VE	06/28/2001         Tongtong Wang         210121.455C16           7590         10/24/2003         EXAM           LLECTUAL PROPERTY LAW GROUP PLLC         CHEN. SI           VE         ART UNIT

DATE MAILED: 10/24/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
Office Action Summary		09/897,778	WANG ET AL.	
		Examin r	Art Unit	
		Shin-Lin Chen	1632	
	The MAILING DATE of this communication a			
Period fo	, •			
THE - Externation - If the - If NO - Failu - Any	CORTENED STATUTORY PERIOD FOR REF MAILING DATE OF THIS COMMUNICATION insions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a received for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by state reply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a repeply within the statutory minimum of thirty od will apply and will expire SIX (6) MONT tute, cause the application to become ABA	ply be timely filed  (30) days will be considered timely.  HS from the mailing date of this communication.  INDONED (35 U.S.C. § 133).	
1)🛛	Responsive to communication(s) filed on 02	2 September 2003 .		
2a)⊠	This action is <b>FINAL</b> . 2b)	This action is non-final.		
3)[	Since this application is in condition for allo			
Disposit	closed in accordance with the practice unde ion of Claims	er <i>Ex par</i> te Quayle, 1935 C.D	. 11, 453 O.G. 213.	
4)⊠ Claim(s) 1,3-6,9-11 and 15-23 is/are pending in the application.				
	4a) Of the above claim(s) <u>1,3-6,9-11 and 15-</u>	19 is/are withdrawn from con	sideration.	
5)	Claim(s) is/are allowed.			
•	Claim(s) <u>20-23</u> is/are rejected.			
·	Claim(s) is/are objected to.			
•	Claim(s) are subject to restriction and ion Papers	d/or election requirement.		
9)[	The specification is objected to by the Exami	ner.		
10)	The drawing(s) filed on is/are: a)☐ acc	cepted or b) objected to by th	e Examiner.	
_	Applicant may not request that any objection to			
11)[	The proposed drawing correction filed on		sapproved by the Examiner.	
40\[	If approved, corrected drawings are required in	• •		
•	The oath or declaration is objected to by the	Examiner.		
	under 35 U.S.C. §§ 119 and 120		440(-) (1) (0)	
•	Acknowledgment is made of a claim for fore All b) Some * c) None of:	ign priority under 35 U.S.C. §	119(a)-(d) or (f).	
	1. Certified copies of the priority docume	ents have been received.		
	2. Certified copies of the priority docume	ents have been received in Ap	plication No	
* (	Copies of the certified copies of the prapplication from the International I See the attached detailed Office action for a limited.	Bureau (PCT Rule 17.2(a)).		
	Acknowledgment is made of a claim for dome	·		
	a)   The translation of the foreign language p	• •		
	Acknowledgment is made of a claim for dome	· · · · · · · · · · · · · · · · · · ·		
Attachmer	nt(s)			
2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of Ir	ummary (PTO-413) Paper No(s)  Iformal Patent Application (PTO-152)	

Application/Control Number: 09/897,778 Page 2

Art Unit: 1632

#### DETAILED ACTION

Applicants' amendment filed 9-2-03 has been entered. Claims 13 and 14 have been canceled. Claims 1, 3-6, 9-11 and 15-23 are pending and claims 20-23 are under consideration.

1. This application contains claims 1, 3-6, 9-11 and 15-19 drawn to an invention nonelected with traverse in Paper No. 12. A complete reply to the final rejection must include cancelation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

## Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

## Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims 20-23 remain rejected under 35 U.S.C. 102(a) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Chen et al., WO 99/54738.

Applicants argue that Chen does not teach that a polypeptide comprising SEQ ID No. 176 or any portion thereof can stimulate T cells and Chen does not teach an immunogenic composition comprising the polypeptide and an adjuvant that induces a predominatly Th1-type

Art Unit: 1632

response (amendment, p. 13-14). This is not found persuasive because of the reasons set forth in the preceding Official action mailed 5-1-03. Chen teaches a composition comprising the cancer associated antigens, CT7, KOC-2 and KOC-3, and a pharmaceutically acceptable adjuvant, and related cancer associated protein KOC-1. Chen also teaches that each of those antigens provides antibodies when expressed in a subject. Since KOC-1 has amino acid sequence that is 100% identical to SEQ ID No. 176 and KOC-1, which is encompassed by the claimed polypeptides, is a cancer associated antigen, one of ordinary sill in the art at the time of the invention would be motivated to combine KOC-1 polypeptide with an adjuvant to induce immune response for the production of antibody as taught by Chen with reasonable expectation of success. Further, since KOC-1 has amino acid sequence that is 100% identical to SEQ ID No. 176, it is inherent for KOC-1 to induce a predominantly Th1-type response. Therefore, claims 20-23 remain rejected under 35 U.S.C. 102(a) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Chen.

#### Conclusion

No claim is allowed.

5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

Art Unit: 1632

date of this final action.

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (703) 305-1678. The

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds can be reached on (703) 305-4051. The fax phone number for this group is (703) 872-9306.

examiner can normally be reached on Monday to Friday from 9:30 am to 6 pm.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

52/ha

Shin-Lin Chen, Ph.D.